Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 20.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 225,328 shares of the biotechnology company’s stock after buying an additional 38,090 shares during the period. Ensign Peak Advisors Inc owned about 0.24% of Sarepta Therapeutics worth $35,602,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in SRPT. Principal Securities Inc. purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter worth about $26,000. Mather Group LLC. purchased a new stake in Sarepta Therapeutics during the 1st quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. raised its position in shares of Sarepta Therapeutics by 125.0% in the 1st quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $31,000. Finally, New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter valued at approximately $32,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 0.1 %

Shares of NASDAQ:SRPT opened at $127.21 on Friday. Sarepta Therapeutics, Inc. has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The company has a market cap of $12.02 billion, a PE ratio of 1,156.45 and a beta of 0.81. The company’s 50-day moving average price is $137.26 and its 200 day moving average price is $132.66.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million for the quarter, compared to analysts’ expectations of $394.38 million. During the same quarter in the previous year, the company posted ($0.27) earnings per share. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. Sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 1.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SRPT has been the topic of several recent analyst reports. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Robert W. Baird upped their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, June 21st. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. BMO Capital Markets boosted their price objective on Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Finally, UBS Group lifted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Three research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $187.39.

Insiders Place Their Bets

In other news, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Bilal Arif sold 7,859 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at $3,467,243.88. The disclosure for this sale can be found here. In the last quarter, insiders sold 52,801 shares of company stock worth $8,399,586. 7.70% of the stock is owned by company insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.